ELIAS Animal Health is conducting a pilot study to evaluate the safety and preliminary efficacy of the ELIAS Cancer Immunotherapy (ECI®), ELIAS’s vaccine-enhanced adoptive T cell therapy, following chemotherapy as treatment for lymphoma in dogs.
Trial participants will first receive eight (8) weekly doses of VCAA (L-asparaginase, vincristine, cyclophosphamide, and doxorubicin) chemotherapy in order to achieve a remission status. Once in remission, patients will receive ECI and will be monitored for 18 months to assess safety and disease-free interval. Overall survival time will also be evaluated.
ELIAS has developed a unique immunotherapy treatment protocol which may permit the dog’s immune system to attack its own cancer cells. In previous clinical trials, this adoptive T cell therapy approach has demonstrated effectiveness against solid tumors in both canines and humans.
This pilot study is being conducted at a single investigator site and enrollment is on a limited basis.